ASHP/SCCM COVID-19 Pharmacology Debates: Anticoagulant and Immunomodulator Use

Activity Type: Knowledge-based 
CE Credit: No CE is offered with this activity.
Activity Fee: Members/Non-Members – Free

Overview

Expert faculty members from the American Society of Health-System Pharmacists (ASHP) and the Society of Critical Care Medicine (SCCM) team up to debate immunomodulatory therapies and approaches to anticoagulation in patients with COVID-19. This joint webinar was moderated by ASHP and SCCM Presidents.

Learning Objectives

  • Describe approaches to thromboembolism prevention in hospitalized patients with or suspected of having COVID-19
  • Explore considerations for escalating antithrombotic regimens in COVID-19
  • Determine if extended prophylaxis upon discharge is warranted in COVID-19 patients without a recent thromboembolism
  • Identify place in therapy for convalescent plasma in COVID-19
  • Discuss rationale for use of IL-6 inhibitors for COVID-19
  • Analyze the use of corticosteroids for treatment of COVID-19
  • Describe the current limitations regarding the use of convalescent plasma, tocilizumab, and corticosteroids for COVID-19
  • Discuss potential places in therapy for immunomodulatory treatments for COVID-19

Speakers

William Dager, Pharm.D., BCPS, MCCM, FASHP, FCCP, FSCHP
Pharmacist Specialist
University of California, Davis Medical Center

Allison E. Burnett, Pharm.D., PhC, CACP
Antithrombosis Stewardship Pharmacist
University of New Mexico Health Sciences Center 

Andrea Nei, PharmD, BCPS, BCCCP
Medical and Surgical/Trauma ICU Clinical Pharmacist
Mayo Clinic

Brian Dee, Pharm.D., BCCCP, BCNSP, FCCM
Clinical Pharmacy Specialist - Critical Care/Nutrition Support
The University of Texas MD Anderson Cancer Center